Target

ATRX

85 products, 78 indications

Indications
Platinum-resistant recurrent ovarian carcinoma (6 products)
glioblastoma (5 products)
Metastatic Cancer (4 products)
NSCLC (4 products)
platinum-resistant high-grade serous ovarian cancer (4 products)
stage IV NSCLC (4 products)
metastatic melanoma (4 products)
Metastatic Castration-Resistant Prostate Cancer (3 products)
stage III non-small cell lung cancer (3 products)
unresectable stage 3 NSCLC (3 products)
unresectable stage IIIA/IIIB NSCLC (3 products)
ovarian cancer (3 products)
Ovarian Cancer (3 products)
Advanced Epithelial Ovarian Cancer (2 products)
extensive-stage SCLC (2 products)
advanced malignancies (2 products)
biliary tract cancer (2 products)
advanced urothelial carcinoma (2 products)
Unresectable hepatocellular carcinoma (2 products)
metastatic non-small cell lung cancer (2 products)
Low-grade serous ovarian cancer (2 products)
stage IV metastatic melanoma (2 products)
Platinum-sensitive recurrent ovarian carcinoma (2 products)
high grade serous ovarian carcinoma (2 products)
platinum-resistant/refractory epithelial ovarian cancer (2 products)
Resectable Pancreatic Ductal Adenocarcinoma (1 products)
metastatic soft tissue sarcoma (1 products)
advanced, metastatic solid tumors (1 products)
pancreatic cancer (1 products)
Oligometastatic pancreatic ductal adenocarcinoma (1 products)
non-metastatic castration-resistant prostate cancer (1 products)
MSI-H metastatic castration-resistant prostate cancer (1 products)
oesophageal squamous cell carcinoma (1 products)
Advanced extrahepatic cholangiocarcinoma and gallbladder cancer (1 products)
Stage IIIA NSCLC (1 products)
EGFR-negative refractory advanced NSCLC (1 products)
Endometrial and ovarian cancer (1 products)
Advanced/metastatic osteosarcoma (1 products)
Advanced soft tissue sarcoma (1 products)
Unresectable locally advanced/locally recurrent esophageal cancer or esophagogastric junction cancer (1 products)
recurrent or metastatic head and neck squamous cell carcinoma (1 products)
Advanced ovarian cancer and colorectal cancer (1 products)
metastatic cutaneous melanoma (1 products)
Advanced or metastatic gastrointestinal cancers (colorectal, gastric, gastroesophageal) (1 products)
metastatic castration-sensitive prostate cancer (1 products)
metastatic ovarian cancer (1 products)
Early stage epithelial ovarian cancer (1 products)
Advanced high-grade ovarian cancer (1 products)
Unresectable ovarian cancer (1 products)
recurrent advanced ovarian cancer (1 products)
High-risk non-muscle invasive bladder cancer (1 products)
Prostate cancer (1 products)
Lung cancer (1 products)
resectable stage II - III non-small cell lung cancer (1 products)
melanoma or lung cancer with autoimmune disease (1 products)
melanoma or lung cancer without autoimmune disease (1 products)
resectable squamous non-small cell lung cancer (1 products)
Advanced melanoma (1 products)
mucosal melanoma (1 products)
Unresectable Melanoma (1 products)
Melanoma and Merkel Cell Carcinoma (1 products)
high-risk stage IIIB–IV cutaneous melanoma (1 products)
urothelial carcinoma (1 products)
relapsed/refractory NSCLC (1 products)
HER2-low metastatic breast cancer (1 products)
Pregnancy-associated melanoma (1 products)
Gastroesophageal Junction Adenocarcinoma, Gastric Cardia Adenocarcinoma (1 products)
hepatocellular carcinoma (1 products)
Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma (1 products)
Locally advanced non-small cell lung cancer (1 products)
HR+/HER2- early-stage breast cancer (1 products)
NRAS-mutant unresectable stage III or IV melanoma (1 products)
advanced non-squamous NSCLC (1 products)
recurrent ovarian, fallopian tube and primary peritoneal cancer (1 products)
Non-Small Cell Lung Cancer (1 products)
recurrent ovarian cancer (1 products)
Unresectable stage III non-small cell lung cancer (1 products)
Melanoma (1 products)
Loading...

1 product

1 drug

6 abstracts

Abstract
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Tempus Labs, Inc., David Geffen School of Medicine UCLA, Ohio State University Comprehensive Cancer Center,
Abstract
Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.
Org: Memorial Sloan Kettering Cancer Center,
Abstract
Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.
Org: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Vander Ingram Cancer Center, Division of Epidemiology and Community Health,
Product
TMZ
Abstract
Glioblastoma in elderly patients: A retrospective analysis of survival and response based on molecular and clinical characteristics—Experience in our centre.
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Cruces University Hospital, Hospital Universitario Cruces, Hospital Universitario de Cruces, IMQ Zorrotzaurre,
Abstract
Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer.
Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea,
Abstract
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitario 12 de Octubre, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO), Institut Catala d'Oncologia Badalona,
Drug
AN0025